Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6

Treatment options and patient perspectives in the management of fibromyalgia: future trends

Authors Kim Lawson

Published 5 December 2008 Volume 2008:4(6) Pages 1059—1071

DOI http://dx.doi.org/10.2147/NDT.S3468

Review by Single-blind

Peer reviewer comments 4

Kim Lawson

Biomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, UK

Abstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological and non-pharmacological (education and exercise) interventions. It is a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, sleep dysfunction, and fatigue, where the pathophysiology could include dysfunction of the central nervous system pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Recently, drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have been identified that demonstrate a multidimensional efficacy in this condition. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies.

Keywords: fibromyalgia, pain, sleep dysfunction, fatigue, exercise, pharmacological treatments

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen

Perri F, Pisconti S, Conson M, Pacelli R, Della Vittoria Scarpati G, Gnoni A, D’Aniello C, Cavaliere C, Licchetta A, Cella L, Giuliano M, Schiavone C, Falivene S, Di Lorenzo G, Buonerba C, Ravo V, Muto P

OncoTargets and Therapy 2015, 8:1345-1349

Published Date: 8 June 2015

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes

Dardano A, Bianchi C, Del Prato S, Miccoli R

Vascular Health and Risk Management 2014, 10:465-475

Published Date: 5 August 2014

Preparation and controlled-release studies of a protocatechuic acid-magnesium/aluminum-layered double hydroxide nanocomposite

Barahuie F, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S, Zainal Z

International Journal of Nanomedicine 2013, 8:1975-1987

Published Date: 20 May 2013

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation

Ozasa R, Hotta M, Yoshimura H, Nakanishi T, Tamaki T, Fujita S, Nakamichi N, Miyaji M, Ishii K, Ito T, Nomura S

International Medical Case Reports Journal 2012, 5:39-43

Published Date: 6 July 2012

Differential effects of nanoselenium doping on healthy and cancerous osteoblasts in coculture on titanium

Phong A Tran, Love Sarin, Robert H Hurt, et al

International Journal of Nanomedicine 2010, 5:351-358

Published Date: 10 May 2010

The rate of symptomatic improvement of congenital nasolacrimal duct obstruction in Japanese infants treated with conservative management during the 1st year of age

Hirohiko Kakizaki, Yasuhiro Takahashi, Shinsuke Kinoshita, Kunihiko Shiraki, Masayoshi Iwaki

Clinical Ophthalmology 2008, 2:291-294

Published Date: 6 June 2008

RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker ανβ3 integrin with MR T1 mapping

Tianyi Ke, Eun-Kee Jeong, Xuli Wang, Yi Feng, Dennis L Parker, Zheng-Rong Lu

International Journal of Nanomedicine 2007, 2:191-199

Published Date: 15 July 2007